Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Safer Pregnancy Alliance [OSPREA] and the Oxford Vaccine Group [OVG] have recently undertaken a successful recruitment drive for a study of maternal immunisation to prevent infant Respiratory Syncytial Virus [RSV] infection.

This is the first collaboration of its kind in Oxford, and the support provided by the Clinical Research Network Thames Valley and South Midlands has contributed to Oxford being the highest recruiting centre in the United Kingdom for this multinational, multi-centre study.

Babies born to participating mothers will now be followed up by paediatric staff at the Oxford Vaccine Group over winter to see if maternal immunisation is able to protect against this common but potentially life threatening virus. Particular credit should go to all the nurses, doctors, midwives and support staff of the two research teams, and it is expected that this will be the first of many such collaborations.

Similar stories

Oxford University extends COVID-19 vaccine study to children

COVID-19 Research

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

World Health Organization experts provide guidance on use of the Oxford vaccine

COVID-19 Research

WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Research

The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford vaccine stimulates broad antibody and T cell functions

COVID-19 Publication Research

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.

SIMON Says…

Publication Research

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.